Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with advanced kidney cancer (aRCC) or advanced bladder/urinary tract cancer (aUBC):
- People of any gender who have advanced kidney cancer or advanced bladder/urinary tract cancer that has spread locally, cannot be removed by surgery, or has spread to other parts of the body
- People who are at the start of their first treatment for this advanced cancer (first-line systemic treatment)
- People who are aged 18 or older
- People who are able to provide written consent to participate
For people with high-risk muscle-invasive urinary tract cancer (MIUC):
- People with a confirmed diagnosis of muscle-invasive cancer of the lower or upper urinary tract, including mixed cell types where the main component is urothelial carcinoma
- People who had radical surgery (such as full bladder removal or kidney/ureter removal) between October 1, 2021 and October 31, 2024
- People aged 18 or older at the time of their surgery
- People whose cancer is considered high-risk for coming back after surgery, based on specific pathology results showing tumour and/or lymph node involvement without detectable spread to other organs at the time of surgery (confirm with trial site)
- People who are able to provide written consent, or in the case of deceased patients, their data may still be included without consent (confirm with trial site)
Who may not be able to join:
For people with advanced kidney or bladder/urinary tract cancer (aRCC or aUBC):
- People who have already received systemic (whole-body) treatment for their advanced cancer before joining
- People who are not receiving any systemic treatment for their advanced cancer
For people with high-risk muscle-invasive urinary tract cancer (MIUC):
- People who had only a partial removal of the bladder or kidney as their main surgical treatment, rather than full radical surgery
- People whose cancer had already spread to other parts of the body (metastatic disease) at the time of surgery
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Staehler, Prof. Dr., Ludwig Maximilian University of Munich, Dept. of Urology - University Hospital, Munich, Germany
Phone: +49 761 15242-0
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Course of treatment (treatment reality)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.